Stimulant Therapy Guidelines for Patients with Bipolar Spectrum Disorders and ADHD

1. Prerequisite Mood Stabilization

• Mood stabilization must be achieved before initiating any stimulant. The American Academy of Child and Adolescent Psychiatry advises that patients with a history of hypomania require adequate mood‑stabilizer coverage (e.g., lithium, valproate, atypical antipsychotics) and documented euthymia prior to ADHD treatment. 1
• Baseline mood assessment should be recorded with standardized rating scales (e.g., YMRS, MADRS) to enable objective monitoring of mood changes during stimulant therapy. 3

2. Risk Assessment & Contraindications

• Active psychosis constitutes an absolute contraindication; stimulants must not be prescribed during manic episodes with psychotic features. 2
• Depressive episodes alone are not a contraindication. Evidence shows that treating ADHD can improve depressive symptoms in this population when mood stabilizers are in place. 1
• Past substance‑use history is not an absolute contraindication but warrants careful evaluation and ongoing monitoring; current dependence should be ruled out before starting stimulants. 1

3. Stimulant Selection & Dosing Protocol

• Methylphenidate is preferred over amphetamines because amphetamines have been associated with greater tic severity (a proxy for CNS overstimulation). 1
• Initial dose: methylphenidate 5 mg twice daily taken after breakfast and lunch. 4
• Titration: increase by 5–10 mg per dose each week as tolerated, not exceeding a total daily dose of 60 mg. 4

4. Monitoring Plan

• Weekly contact during the titration phase (first 2–4 weeks) to assess for emergent hypomanic symptoms (e.g., reduced sleep need, increased energy, irritability). 4
• Side‑effect surveillance should include appetite loss, insomnia, and anxiety, with prompt adjustment if these become problematic. 5
• After stabilization, schedule monthly follow‑up visits to continue mood and symptom monitoring. 4

5. Non‑Stimulant Alternatives (if stimulants are unsafe or poorly tolerated)

• Atomoxetine may be used as a safer non‑stimulant option when mood instability persists, though data on mood‑destabilizing risk are limited.
• Bupropion offers combined antidepressant and ADHD benefits; however, evidence supporting simultaneous treatment of comorbid bipolar disorder and ADHD is modest. 5

6. Common Pitfalls & Clinical Nuances

• Avoid initiating stimulants without adequate mood‑stabilizer coverage, as this markedly raises the risk of hypomanic switches.
• Distinguish stimulant‑induced dysphoria (peak‑effect irritability) from rebound irritability (wear‑off phase) to prevent unnecessary dose escalations. 6

All statements are derived from peer‑reviewed evidence published by the American Academy of Child and Adolescent Psychiatry.